Clinical data | |
---|---|
Other names | LEO-1727; 19-Nortestosterone 17β-N-(2-chloroethyl)-N-nitrosocarbamate; Nandrolone chloroethylnitrosocarbamate |
Routes of administration | Intramuscular injection |
Drug class | Cytostatic antineoplastic agent; Androgen; Anabolic steroid; Androgen ester; Progestogen |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H29ClN2O4 |
Molar mass | 408.92 g·mol−1 |
3D model (JSmol) | |
| |
|
LS-1727 (also known as nandrolone 17β-N-(2-chloroethyl)-N-nitrosocarbamate) is a synthetic, injected anabolic–androgenic steroid (AAS) and a nitrosocarbamate ester of nandrolone (19-nortestosterone) which was developed as a cytostatic antineoplastic agent but was never marketed.[1][2][3][4]
Compound | PR | AR | ER | GR | MR | SHBG | CBG |
---|---|---|---|---|---|---|---|
Nandrolone | 20 | 154–155 | <0.1 | 0.5 | 1.6 | 1–16 | 0.1 |
Testosterone | 1.0–1.2 | 100 | <0.1 | 0.17 | 0.9 | 19–82 | 3–8 |
Estradiol | 2.6 | 7.9 | 100 | 0.6 | 0.13 | 8.7–12 | <0.1 |
Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PR , testosterone for the AR , estradiol for the ER , dexamethasone for the GR , aldosterone for the MR , dihydrotestosterone for SHBG , and cortisol for CBG . Sources: See template. |